Moreover, serum albumin, among its heterogeneous applications in the risk stratification of PBC patients, recently emerged also as a robust and accessible biomarker of clinically significant portal hypertension (CSPH), particularly in settings where transient elastography is unavailable or unreliable due to cholestatic interference (see the dedicated paragraph for details) [158]. This evidence concerns the gene ALB and primary biliary cholangitis.